Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

Michael G. Kharas(Memorial Sloan Kettering Cancer Center), Vanessa M. Scarfone, Zachary A. Knight(Howard Hughes Medical Institute), Matthew R. Janes(University of California, Irvine), Kevan M. Shokat(Howard Hughes Medical Institute), Michael B. Lilly(Medical University of South Carolina)
Journal of Clinical Investigation
August 14, 2008
Cited by 150


Related Papers